Glucocorticoid receptor modulators to treat cervical cancer
US10898478B2 · kind B2 · utility
11Cited by
37References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 14, 2020 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Jan 14, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.